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Abstract 
Background 
Microvascular dysfunction (MvD) is a predictor of outcomes in coronary heart disease 
(CHD). Activated platelets interact with leukocytes forming platelet monocyte aggregates 
(PMA), a marker of platelet activation. 
Objectives 
To assess the relationship between MvD and PMA expression in CHD patients treated with 
percutaneous coronary intervention (PCI). 
Methods 
Fourteen patients with NSTE-ACS and 11 patients with stable angina (SA) recruited. Blood 
samples aspirated sequentially from the right atrium (RA), ascending aorta (AO) and the 
coronary artery (CO) distal to the culprit lesion. MvD was assessed by measuring the index of 
microvascular resistance (IMR), coronary flow reserve (CFR) and the coronary wedge 
pressure (Pw). Flow cytometry was used for PMA estimation.  
Results 
Total PMA and CD62P+PMA did not differ between CO, AO and RA in the two groups. 
CD62P+PMA expression in the CO and AO of the ACS group were higher compared to SA 
(p=0.005 and p=0.03 respectively). Pw (median) was higher in the ACS (52.5 mmHg) 
compared to the SA group (18 mmHg) p= 0.01. IMR and CFR did not differ between ACS 
and SA. Pw and IMR in both groups correlated positively with the total PMA (r2=0.3; 
p=0.009 and r2=0.4; p=0.01 for Pw and IMR respectively in ACS, r2=0.2; p=0.03 and r2=0.3; 
p=0.01 for Pw and IMR respectively in SA). 
Conclusions 
Elevated CD62+PMA is a hallmark of ACS. PMA correlate with measured microvascular 
dysfunction in both stable angina and ACS patients. This study supports the hypothesis that 
PMA may be important determinants of platelet activation, inflammation and microvascular 
dysfunction in CHD.  
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Background 
Microvascular dysfunction (MvD) is a powerful independent predictor of long term 
outcomes, left ventricular function and mortality, in patients presenting with acute coronary 
syndrome (ACS) and undergoing revascularization with percutaneous coronary intervention 
(PCI). REFERENCE REQUIRED Despite angiographic successful coronary artery stenting 
potential compromise of the coronary microcirculation during or after PCI is associated with 
“slow flow” or “no flow” with subsequent impaired myocardial tissue oxygenation. 
REFERENCE REQUIRED A number of different non-invasive and invasive techniques have 
been developed to evaluate the coronary microvasculature. Among the invasive methods in 
the catheter laboratory the ‘Index of microvascular resistance’ (IMR) which is derived using 
a Doppler or a pressure-temperature sensing wire, has emerged as a novel index for the 
assessment of the coronary microcirculation (1-3). 
Fearon et al demonstrated positive correlation of IMR measured immediately following 
primary PCI (pPCI) for STEMI patients with peak CK and left ventricular function assessed 
by echocardiography at 3 months follow up (4). It has also been shown that measured IMR 
during pPCI, in STEMI patients, predicts myocardial salvage, infarct characteristics, and left 
ventricular ejection fraction (5-7). Cuisset et al has demonstrated, in patients with stable 
angina who had elective PCI, that direct stenting was associated with significantly lower IMR 
compared to the patients who had pre-dilation with balloon. They have also demonstrated that 
patients with post-PCI troponin release had significantly higher IMR compared to the patients 
without post-PCI troponin release (8). In addition measurement of IMR in patients electively 
admitted for PCI may allow prospective identification of patients at risk of periprocedural 
myocardial infarction (9). 
Activated endothelial cells and platelets express P-selectin on their surface which mediates 
the platelet-leukocyte interaction via the P-selectin-PSGL-1 bond leading to platelet 
monocyte aggregate (PMA) formation with leukocyte activation, migration and recruitment 
at the site of inflammation (10;11). It has been shown that inflammatory mediators such as 
tumour necrosis factor-α (TNF-α) and LPS increase P-selectin production from the 
endothelial cells in addition to up-regulating P-selectin on the cell surface (12). Furthermore, 
activated platelets lose their surface P-selectin despite the fact they continue to circulate and 
function (13). Therefore PMA measurement may represent a more robust marker of platelet 
activation than detection of P-selectin on their surface. P-selectin on the surface of the 
activated platelets, within the PMA complex, induces monocyte TF expression which, in the 
ACS setting with a ruptured atheromatous plaque, may trigger or contribute to the cascade of 
athero-thrombosis (14). PMA levels, both at the site of the coronary lesion and 
systematically, has been described as a sensitive marker of platelet activation and 
inflammation. Increased PMA levels have been observed in both stable angina (15;16) and 
ACS patients (17). The extent of PMA formation depends mainly on platelet activation status 
rather than the monocyte activation (18). It has been shown that prevention of platelet 
adhesion to monocytes by interfering with the binding of platelet P-selectin to PSGL-1 
reduces inflammation (19). Platelet binding to monocytes via the P-selectin depandant 
pathway increases the adhesive properties of monocytes by up-regulating the expression and 
functionality of beta1 and beta2 integrins (20;21). This process is facilitated by the presence 
of RANTES and CXCL10 chemokines produced by platelets on to the monocytes (22). A 
positive relationship between inflammatory markers (IL6 and CRP) and markers of platelet 
activation like P-selectin and PMA has been previously demonstrated (23). Therefore the 
possibility that PMA may contribute in the pathophysiology of microvascular dysfunction via 
exaggerating and sustaining the coagulation cascade in addition to perpetuating local 
coronary inflammation exist.  
The role of PMA formation in the pathophysiology of ACS remains unknown. Whether PMA 
is just a bystander of the inflammatory and thrombotic process occurring in the setting of 
ACS or whether the PMA is an effector of the disease remains unclear. EXPLAIN HERE 
EXACTLY WHAT A CD62+ PMA IS Botto et al have demonstrated increased platelet-
monocyte interaction and CD62P+PMA formation in blood samples aspirated from the 
infarct related artery (IRA) compared with the peripheral circulation in patients presented 
with myocardial infarction (24). The concept of an active involvement of PMA in ACS has 
been supported with the observations by Patel et al who demonstrated trans-coronary gradient 
of platelet-leukocyte formation in patients with ACS. They found increased CD62P+PMA 
level in the coronary sinus samples compared to the aortic samples in both patients with ACS 
and stable angina (25). In addition, recent data suggest that platelet monocyte interaction is a 
normal physiological process in the absence of overt platelet activation with little impact on 
the potential of monocytes to cause vascular injury (26). We identified this subpopulation of 
PMA as P-selectin positive PMAs (CD62+ PMAs). We hypothesized that 1) PMA is higher 
in the ACS group compared with the stable angina and 2) a positive correlation should exist 
between PMA expression and markers of microvascular dysfunction. The aim of our study 
was to assess the relationship between microvascular dysfunction and the level of PMA 
expression, intracoronary and systemic (aorta and right atrium) in patients presenting with 
NSTE-ACS or stable angina treated with PCI. 
Methods 
Study population 
Twenty five patients (14 patients with NSTE-ACS and 11 patients with stable angina (SA) 
presenting to our hospital with symptomatic coronary heart disease and treated with PCI were 
recruited for the study. The diagnosis of NSTE-ACS was based on the history of chest pain 
with or without ischaemic ECG changes (other than ST elevation) and a troponin T value > 
0.03 ng/l (27). SA patients were admitted electively for PCI. SA patients had been reviewed 
in the cardiology outpatient clinic with a diagnosis of angina pectoris based on typically 
ischaemic sounding chest pain and a positive non-invasive test such as exercise tolerance test, 
stress echocardiography or myocardial perfusion scan. The decision for diagnostic 
angiography was made by a cardiologist as part of routine clinical care. Informed consent 
was obtained prior to the procedure from all recruited patients outside the cardiac 
catheterisation laboratory. Ethical permission was granted by the local ethics committee of 
the Royal Free Hospital, and all participants provided fully informed written consent. 
 
Exclusion criteria 
Patients with a history of chronic renal failure (defined as an estimated GFR<60ml/min), 
prior coronary artery bypass grafts and patients who had received Glycoprotein IIb/IIIa 
antagonists prior to sampling were excluded from the study. 
 
Coronary angiography, coronary angioplasty and blood sampling 
Diagnostic coronary angiography followed by PCI was performed according to contemporary 
guidelines (27). Through a 6F venous sheath via the femoral vein a 5F multipurpose catheter 
(5F, Cordis ®, internal diameter 0.11cm) was placed in the right atrium. Left and right 
coronary artery angiography was performed with a 5F Judkin’s Left 4 diagnostic catheter 
(Cordis ®, internal diameter 0.11 cm) and 5F Judkin’s Right 4 diagnostic catheter (5F, Cordis 
®, internal diameter 0.11 cm) respectively. Blood samples (10 ml from each site) were 
aspirated sequentially through the diagnostic 5F catheter from the right atrium and ascending 
aorta. After identification and wiring of the culprit lesion an aspiration catheter (Medtronic ® 
Export catheter, internal diameter 0.10 cm) was advanced just distal to the culprit lesion and 
10 mls blood sample was aspirated. All blood samples were aspirated carefully through 
catheters of similar internal diameter in order to maintain similar shear stress during 
aspiration and minimise shear stress related in vitro platelet activation. PCI was performed 
according to standard procedures following collection of the blood samples.  
NSTE-ACS patients were treated with 300 mg of Aspirin, 600 mg of Clopidogrel and weight 
adjusted low molecular weight heparin (enoxaparin 1mg/kg twice daily) immediately after 
the diagnosis of NSTE-ACS. All patients received weight adjusted unfractionated heparin in 
the catheter laboratory during PCI to maintain the ACT between 200 and 250 sec. SA patients 
were treated with anti-anginal medications; aspirin 75mg od and clopidogrel 75mg od for 7 
days prior to the PCI as per hospital protocol.   
 
Measuring IMR and CFR with pressure-temperature sensor wire 
Thermodilution technique using a 0.014 inch floppy, pressure wire (pressure wire 3, Radi 
Medical system) as described before (3) was used to measure IMR and CFR, in 7 patients 
with NSTE-ACS and 7 patients with SA. The shaft/microsensor of the wire can be used as an 
additional thermistor, providing the input signal at the coronary ostium of any fluid injection 
with a temperature difference from blood. In this manner the mean transit time of the injected 
3 mls 0.9% saline at room temperature, in the coronary artery can be calculated from a 
coronary thermodilution curve. Measurements of the mean transit time (Tm) were calculated 
3 times at baseline and 3 times at maximum hyperaemia. Maximum hyperaemia was 
achieved by adenosine infusion through the femoral vein at a rate 140 µg/kg/min. Distal 
coronary pressure (Pd) was recorded from the pressure wire. Mean aortic pressure (Pa) was 
measured from the coronary catheter and central venous pressure (Pv) was measured from the 
right heart catheter at maximum hyperaemia. Coronary wedge pressure (Pw) was measured at 
maximum hyperaemia by inflating a semi-compliant balloon (1mm smaller that the vessel 
diameter) in the coronary artery. IMR measurements were calculated after the completion of 
the PCI. IMR was calculated using the equation IMR= Pa × Tm × [(Pd-Pw) ÷ (Pa-Pw)] as 
described before (1). All the above measurements were taken during maximum hyperaemia. 
CFR  equals to the ratio of the baseline Tm/hyperaemic Tm provided that the time for 
analysis of the thermodilution equals at least one cardiac cycle, and variability between 
values of  the 3 transit times < 20%.   
 
Flow Cytometry and PMA methodology 
4mls of the sampled whole blood was poured into separate sterile vacutainer tubes containing 
a combination of 3.2% sodium citrate and EDTA for flow-cytometric estimation of PMA and 
CD62P+ PMA as described by our group before (28). Blood samples were immediately 
transferred to the haematology laboratory and prepared for flow cytometry and PMA 
estimation, within 2 hours of sample collection. Five µL of fluorescent monoclonal 
antibodies, anti CD61 FITC, anti CD14 PerCP and anti CD62P PE were added in each of the 
three (one tube for each compartment) round bottom polystyrene tubes (BD Falcon 12 x75 
mm style). One hundred µL of whole blood was aliquoted into each tube. The samples were 
incubated in a dark place at room temperature for 20 minutes. After that, erythrocytes were 
lysed by addition of 2 ml of easy lyse™ solution (Dako) (1 in 10 dilution) for 15 minutes at 
room temperature in dark place. Red blood cells were washed with addition of 1ml of FACS 
flow and centrifuged at 300g for 5 minutes. The supernatant was discarded and the cells 
resuspended in 500 µL of FACS flow for immediate flow cytometric acquisition and analysis 
(FACS Calibur equipped with Cell Quest ® software – BD Biosciences, Oxford, UK). Events 
were acquired on a 2D dot plot arraying CD14 (logarithmic scale abscissa) and SSC height 
(linear scale ordinate). Monocytes were identified as CD14 positive events and distinctive 
intermediate side scatter height. A minimum of 5000 CD14 positive events were acquired 
from each sample. The monocyte population was gated and named as analysis region (R1). 
Events within R1 plotted again on a 2D dot-plot arraying CD 61 signal width (linear scale 
abscissa) and CD14 signal height (logarithmic scale abscissa). Double positive 
CD14+CD61+ events were consider as total PMA and were expressed as percentage of the 
total monocytes. Triple positive CD14+CD61+CD62P+ events were identified as P-selectin 
positive PMA (CD62P+ PMA) and were expressed as percentage of the total PMA. The 
process was standardised in our laboratory with the percentage of PMCs in the peripheral 
circulation of normal healthy individuals was found to be 2.57± 0.31 (CV 13.96± 8.30 %). 
 
Statistical analysis 
Continuous variables were expressed as medians with interquartile range (IQR). Categorical 
variables were expressed as percentages with 95% confidence intervals (95% CIs). 
Comparisons between the two groups and between the compartments were performed using 
the Mann-Whitney U test. Fisher exact test was used for proportions. Linear regression was 
used to correlate the markers of microvascular dysfunction and PMA. A 2-sided p value 
<0.05 were considered to be statistically significant. All statistical analyses were performed 
with Graph Pad Prism 5 statistical software. 
 
Results 
The demographics and baseline characteristics of the study population are shown in table 1. 
Briefly the majority of the study population was male (83%). The SA patients were more 
likely to have past medical history of hypertension compared to the NSTE-ACS group. Also 
the NSTE-ACS patients were more likely to have family history of CHD. The study 
population was well balanced with respect to other risk factors, diabetes mellitus, 
dyslipidaemia and smoking. 
 
 Total PMA expression in the CO, AO and RA sites in NSTE-ACS and SA groups 
Within NSTE-ACS and SA groups there were no difference seen in the expression of total 
PMA and CD62P+ PMA levels between the three sites (CO, AO and RA). Total PMA 
expression in the CO, AO and RA did not differ between NSTE-ACS and SA (Fig 1). 
However the expression of CD62P+ PMA in the CO and AO of the NSTE-ACS patients was 
higher compared to SA patients (p=0.005and p=0.03 respectively) (Fig 1). There was no 
difference in the expression CD62P+ PMA in the RA between the two groups (Fig 1c).  
 
IMR, CFR and Pw in the two groups 
Pw (median (IQR) was higher in the NSTE-ACS group [52.5 mmHg (34.2-65.5)] compared 
with the SA group [18 mmHg (17-32)] p= 0.01] Fig 2. IMR (median (IQR) did not differ 
between NSTE-ACS [19.6 mmHg*sec (14.4-34.2)] and SA group [19.9 mmHg*sec (17.6-
26.8)] (Fig 2). CFR also did not differ between the two groups (data not shown). 
 
Correlations between indices of microvascular dysfunction and PMA in the ACS and 
stable angina groups 
Pw and IMR in the NSTE-ACS correlated positively with the total PMA levels in the three 
compartments (r2=0.35; p=0.009 and r2=0.46; p=0.01 for Pw and IMR respectively). In 
addition there was a strong positive correlation between Pw and CD62P+ PMA (r2=0.46; 
p=0.007). (Table 2) 
In the SA group Pw and IMR correlated positively with total PMA (r2=0.23; p=0.03 and 
r2=0.28; p=0.01 for CwP and IMR respectively). CD62P+ PMA in the SA did not correlate 
with Pw or IMR. (Table 2) 
 
 Discussion 
The unique finding of our study is the positive correlation between invasive markers of 
microvascular dysfunction and PMA in patients with NSTE-ACS and stable angina. In line 
with previous studies, CD62P+ PMA in the coronary were higher in ACS patients compared 
with stable angina. The above findings support the knowledge that platelet activation is 
pivotal in ACS and as such CD62P+ PMA which is a sensitive marker of platelet activation is 
the hallmark of ACS. It also supports the notion that PMA formation is dependent on platelet 
activation and that PMA expression and platelet activation follow the same pattern of 
expression. Concomittant aortic and coronary blood sampling in this study demonstrated that 
CD62+PMA were significantly higher in acute coronary syndrome compared to stable angina 
indicating overspill of activated PMA generated at the site of plaque rupture from coronary to 
aorta. The fact that the NSTE-ACS patients were studied, blood sampling and IMR 
measurements, 2-4 days after the onset of symptoms whilst receiving treatment with anti-
platelet and anti-coagulant medications may have altered the expression of total PMA and 
contributed to our observations that total PMA did not differ between the 2 groups. This may 
also explain the fact that only Pw was higher in the ACS group compared to the SA group 
whilst IMR and CFR did not differ between the 2 groups. The latter is probably due to sample 
size. 
During ACS, PMA formation at the site of plaque rupture with subsequent monocyte 
activation and cytokine release may contribute to the impairment of microcirculatory flow. 
Ko et al have found increased levels of soluble CD40 ligand, IL-6, serotonin, TF and factor 
VII in the culprit coronary artery compared to those in peripheral blood (29). Also a positive 
relationship between inflammatory markers (IL6 and CRP) and markers of platelet activation 
like P-selectin and PMA has been demonstrated by Wang et al (30). Takahashi et al have 
showed that neutrophilia on admission is associated with impaired microvascular reperfusion 
and poor functional recovery in patients with myocardial infarction treated with primary PCI. 
Similar finding were found by Sezer et al (31) who showed that neutrophilia and higher mean 
platelet volume were found to be associated with higher IMR, lower CFR and higher 
coronary wedge pressure in patients with ACS treated with PCI. The results of our study are 
in line with the above findings. Both total PMA and CD62P+ PMA correlated positively with 
the coronary wedge pressure in the ACS patients. Also IMR correlated positively with total 
PMA. Contrary to the above, in the SA group IMR and Pw correlated positively with total 
PMA only but not with CD62P+ PMA.  
Clinical studies in animal models, with coronary artery occlusion and reperfusion, have 
shown that administration of recombinant monoclonal PSGL-1 antibodies targeting the P-
selectin-PSGL interaction results in inhibition of leukocyte-platelet and leukocyte-endothelial 
binding with subsequent improvement of reperfusion in addition to the reduction of the 
infarct size (32-34). However in human beings administration of recombinant PSGL in 
patients with STEMI as an adjunct to thrombolysis have failed to improve clinical outcomes 
like TIMI flow, infarct size and mortality (35). This can be explained by the fact that in both 
studies the recombinant antibody was given intravenously and as such may have failed to 
reach the coronary circulation. This is because the recombinant antibody was human antibody 
and as such was probably absorbed by the antibody receptors expressed on the macrophages 
in the liver and spleen. Recently, Tardif et al have shown that intravenous administration of a 
P-selectin antagonist (inclacumab) in patients with ACS scheduled for PCI reduce myocardial 
damage (36). They found that peak Troponin I and creatine kinase reduced by 23%. Our 
findings may explain the mechanism behind the above positive findings. This raises the 
possibility that PMA may contribute to the pathophysiology of microvascular dysfunction via 
exaggerating and sustaining platelet activation and coagulation cascade in addition to 
perpetuating local coronary inflammation. Therefore, targeting PMA formation in ACS may 
interrupt the platelet-monocyte interactions and limit intra-coronary inflammation and 
thrombus formation. 
 
Conclusions 
In conclusion PMA are increased in patients with ACS compared with stable angina with 
CD62P+ PMA being a hallmark of ACS. PMA and CD62P+ PMA correlated positively with 
indices of microvascular dysfunction. Hence PMA may represent a marker of both platelet 
activation and microvascular dysfunction.  
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Figure legends 
Figure 1 Higher expression of CD62P+ PMA, but not total PMA, in the acute coronary 
syndrome (ACS) compared with the stable angina (SA) group in the coronary and aorta. 
 (Total PMA expressed as % of monocytes and CD62P+ PMA as % of total PMA). PMA 
(platelet monocyte aggregates). Comparisons were performed using the Mann-Whitney U 
test. 
Figure 2 Higher coronary wedge pressure (Pw) in the acute coronary (ACS) compared with 
the stable angina (SA) group. The index of microvascular resistance (IMR) did not differ in 
the two groups. Comparisons were performed using the Mann-Whitney U test. 
Error! Not a valid link. 
Table 1. Baseline characteristics, demographics and angiographic data of the study groups. 
CHD (coronary heart disease), ACS (acute coronary syndrome) 
 
ACS ACS SA SA
PMA vs Pw CD62 + PMA vs Pw PMA vs IMR CD62 + PMA vs IMR PMA vs Pw CD62 + PMA vs Pw PMA vs IMR CD62 + PMA vs IMR
1/slope 4.865 1.438 3.053 -1.174 5.09 2.344 2.971 -2.569
R square 0.3503 0.4603 0.462 0.3183 0.2342 0.07371 0.2823 0.1726
P value 0.0097 0.0076 0.0106 0.0893 0.0306 0.3696 0.0192 0.1096  
Table 2. The table above shows the linear regression analysis including p values of the 
PMA/CD62P+PMA, in the three sites, and indices of microvascular dysfunction. Platelet 
monocyte aggregates (PMA), Coronary wedge pressure (Pw), Index of microvascular 
resistance (IMR) 
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Figure 1 Higher expression of CD62P+ PMA in the acute coronary syndrome compared with 
the stable angina. 
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Figure 2 Higher coronary wedge pressure (Pw) in the acute coronary syndrome compared 
with stable angina. 
 
